Works (1)
Updated: July 5th, 2023 14:34
2020 article
Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers
Coleman, A. E., DeFrancesco, T. C., Griffiths, E. H., Lascelles, B. D. X., Kleisch, D. J., Atkins, C. E., & Keene, B. W. (2020, July 1). Journal of Veterinary Cardiology.
author keywords: Feline; Beta-btocker; Accelerometry
MeSH headings : Administration, Oral; Animals; Anti-Arrhythmia Agents / administration & dosage; Anti-Arrhythmia Agents / therapeutic use; Atenolol / administration & dosage; Atenolol / therapeutic use; Biomarkers / blood; Cardiomyopathy, Hypertrophic / drug therapy; Cardiomyopathy, Hypertrophic / veterinary; Cat Diseases / blood; Cat Diseases / drug therapy; Cats; Double-Blind Method; Female; Male; Quality of Life; Treatment Outcome
topics (OpenAlex): Cardiovascular Conditions and Treatments; Cardiomyopathy and Myosin Studies; Congenital Heart Disease Studies
TL;DR:
This study failed to identify an effect of subclinical HCM on owner-assessed QOL or activity or a treatment effect of atenolol on these variables at the dosage evaluated, and these findings do not support a treatment benefit of atanolol for the goal of symptom reduction in cats with sub clinical HCM.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Sources: Web Of Science, NC State University Libraries, ORCID
Added: September 21, 2020